Clinical Trial Update: A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study of oral SB1518 (pacritinib) in chronic idiopathic myelofibrosis has completed, with the trial listing other myeloproliferative disorders (po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• SB1518 (pacritinib) (pacritinib)

Snippet

Sponsor: S*BIO | Conditions: Myelofibrosis, Myeloproliferative Disorders | Phase 1, Phase 2 | Status: COMPLETED